3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
40
Carcinoma, Non-Small-Cell Lung
40
Carcinoma, Renal Cell
30
Urinary Bladder Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
15
Lung Neoplasms
15
Colorectal Neoplasms
15
Stomach Neoplasms
13
Pancreatic Neoplasms
13
Neoplasms
13
Neoplasm Metastasis
13
Ovarian Neoplasms
11
Sarcoma
10
Hodgkin Disease
10
Glioblastoma
10
Carcinoma, Transitional Cell
10
Rectal Neoplasms
9
Triple Negative Breast Neoplasms
8
Prostatic Neoplasms
8
Kidney Neoplasms
8
Carcinoma, Hepatocellular
8
Small Cell Lung Carcinoma
7
Esophageal Neoplasms
7
Colonic Neoplasms
7
Breast Neoplasms
7
Head and Neck Neoplasms
6
Skin Neoplasms
5
Lymphoma, Large B-Cell, Diffuse
5
Carcinoma, Neuroendocrine
5
Carcinoma, Merkel Cell
5
Interventions
olaparib
4
Abiraterone Acetate
3
Pluvicto
2
rucaparib
1
radium Ra 223 dichloride
1
enzalutamide
1
enfortumab vedotin
1
copanlisib
1
cabazitaxel
1
abiraterone
1
Radium-223
1
Prednisone
1
Prednisolone
1
Nivolumab
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Metastatic Castration-resistant Prostate Cancer
×
Nivolumab
×
Clear all
NCT04109729
2026-06-01
Rad2Nivo
University of Utah
Phase 1
Active not recruiting
39 enrolled